Allison D. Ebert

This study identifies IL-1ra and CCL5 as potential therapeutic targets for SMA by showing they reduce astrocyte-driven inflammation and improve disease outcomes in vitro and in mice.

This paper investigates how HCMV infection affects microtubule networks in human forebrain neurons and shows that stabilizing microtubules reduces syncytia formation and neurite retraction.

The paper tests astrocyte-targeted IL-10 and CCL2 modulation in ALS iPSC models, finding reduced neuroinflammation and altered microglia/motor neuron responses in co-cultures.

This study shows that HCMV can infect and replicate in terminally differentiated human cortical neurons, causing structural and functional changes including altered calcium signaling and neurotransmission.

The paper investigates how the source of HCMV affects neuronal pathogenesis in cerebral organoids and shows that neutralizing antibodies and neurotropic factors can mitigate gene expression dysregulation.

The paper uses SCD patient-derived iPSCs to study sensory neuron function and identifies plasma factors that sensitize neurons to pain stimuli.

This study identifies a non-cell autonomous mechanism in SMA where astrocytic GLAST dysfunction contributes to motor neuron dysfunction, which is partially restored by SMN re-expression.

This study investigates how microglia and astrocytes affect neurofilament accumulation in ALS iPSC-derived motor neurons, showing glial-secreted factors influence neurofilament pathology.

This study assesses CSF biomarkers and microRNA-mediated mechanisms in SMA patients treated with nusinersen, finding improved microRNA expression but persistent cellular stress and astrocyte dysfunction.

This study shows SRCP1 reduces insoluble SOD1 in ALS models but does not extend mouse lifespan.

The paper tests if nicotinamide mononucleotide treatment increases NAD+ levels and sirtuin activity in Parkinson's disease stem cell-derived dopaminergic neurons.